Characterization of POI women profile and cardiovascular risk associated to Hormonal Therapy (HT) or Combined Oral Contraceptives (COC)

• Grant number: 21/06530-8
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: August 01, 2021
• End date: July 31, 2022
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Ana Carolina Japur de Sá Rosa e Silva
• Grantee: Victoria Issa Chodraui
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Premature Ovarian Insufficiency (POI) has serious consequences on women's bodies, including increased risk of cardiovascular diseases secondary to a lack of estrogen exposure. Replacement of physiologic doses of estrogen is of utmost importance. It can be made with combined oral contraceptives (COC) or natural estrogens. Although the latter is usually the first line treatment, there are cases in which the prescription of COC is needed, due both to financial limitations or the necessity of contraceptive methods. Literature is still sparse regarding the impact of these replacement therapies on cardiovascular risk factors in these young women (younger than 40). This project intends to compare clinical profiles and cardiovascular risk factors between women with POI using conventional hormone therapy (natural estrogens) and patients using combined oral contraceptives. This is a retrospective analysis of medical records of patients with POI who follow the outpatient of Endocrine Gynecology in HCFMRP-USP, between January of 2018 and December of 2020. The patients will be evaluated regarding age of onset symptoms, parity, amenorrhea duration, BMI, arterial pressure, symptoms pretreatment, use of other medications, comorbidities, etiology of POI, time frame between star of symptoms and start of treatment, time frame between diagnosis and treatment, and time frame between treatment and improvement of symptoms, physical activities, FSH levels, Prolactin, TSH, anti-TPO dosage, glycemia, lipidic profile, bone mass density (BMD), karyotype, type of hormone replacement therapy (HRT), contraindication of COC, time frame using HRT, use of vitamin D and Calcium. This project intends to compare clinical profiles and cardiovascular risk factors between women with POI using conventional hormone therapy (natural estrogens) and patients using combined oral contraceptives. This is a retrospective analysis of medical records of patients with POI who follow the outpatient of Endocrine Gynecology in HCFMRP-USP, between January of 2018 and December of 2020. The patients will be evaluated regarding age of first symptoms, parity, amenorrhea duration, BMI, arterial pressure, symptoms pretreatment, use of other medications, comorbidities, etiology of POI, time frame between star of symptoms and star of treatment, time frame between diagnosis and treatment, and time frame between treatment and improvement of symptoms, physical activities, FSH levels, Prolactin, TSH, anti-TPO dosage, glycemia, lipidic profile, bone mass density (BMD), karyotype, type of hormone replacement therapy (HRT), contraindication of COC, time frame using HRT, use of vitamin D and Calcium. (AU)